Skip to main content

Table 3 Prognostic factors of disease-free survival

From: Optimal radiotherapy for patients with internal mammary lymph node metastasis from breast cancer

Characteristics

5-year DFS (%)

Univariate

p-value

Multivariate

p-value

HR

(95% CI)

Age

≤40 years (n = 38)

85.5%

0.007

0.012

0.301

(0.118–0.767)

> 40 years (n = 46)

60.7%

Tumor subtype1)

Non-TNBC (n = 54)

80.7%

0.012

< 0.001

0.189

(0.079–0.453)

TNBC (n = 30)

56.7%

cT stages

1–2 (n = 47)

77.9%

0.090

0.070

0.442

(0.183–1.068)

3–4 (n = 37)

64.8%

cN stages

2b or 3b (n = 63)

72.1%

0.576

–

–

3c (n = 21)

71.4%

Malignant cells on FNABx of the IMN

(−) or unknown (n = 44)

73.7%

0.610

–

–

(+) (n = 40)

65.4%

Extent of IMN

Single ICS (n = 37)

74.9%

0.525

–

–

Multiple ICS (n = 47)

63.4%

IMN long diameter

< 1.0 cm (n = 42)

87.9%

0.002

< 0.001

0.157

(0.060–0.412)

≥1.0 cm (n = 42)

56.4%

Neoadjuvant chemotherapy

Performed (n = 66)

72.1%

0.927

–

–

Not performed (n = 18)

71.1%

Axillary surgery

ALND (n = 74)

69.5%

0.184

0.056

8.003

(0.947–67.663)

SLNB (n = 10)

90.0%

EQD2 of the IMN2)

50.0–63.5 Gy (n = 35)

65.1%

0.188

0.029

2.491

(1.095–5.663)

63.6–70.4 Gy (n = 49)

76.6%

  1. 1)TNBC was defined as tumors that were negative for the estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 on immunohistochemical staining of the breast tumor
  2. 2)Radiotherapy dose was calculated using the EQD2 assuming the α/β ratio of 3.5 Gy
  3. Abbreviations: DFS Disease-free survival, TNBC Triple-negative breast cancer, FNABx, fine needle aspiration biopsy, IMN Internal mammary node, ICS Intercostal space, ALND Axillary lymph node dissection, SLNB Sentinel lymph node biopsy; HR Hazard ratio; CI Confidence interval, EQD2 Biologically equivalent dose in 2 Gy fractions
Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us